JW Pharmaceutical

jw-pharma.co.kr

Total trials

77

Active

7

Phase 3

16

Total enrollment

60,744

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 14 of 14 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Empagliflozin/Metformin1
Metformin1
Empagliflozin/Linagliptin1
Ezetimibe 10 mg1
Anagliptin4
Pitavastatin 4mg2
JW0104+C24021
JW0104+C24031
C24021
KLH-2109+ Leurprorelin acetate Placebo1
KLH-2109 Placebo + Leurprorelin acetate1
JW22861
JW0061 SAD1
JW0061 MAD1

Next readouts

  • 2025-11
  • 2026-01-22
  • 2026-04
  • 2026-12-31
  • 2027-03-31
  • 2028-03-31

Top conditions

  • Healthy18
  • Hypercholesterolemia7
  • Type 2 Diabetes Mellitus6
  • Hypertension5
  • Gout4
  • Dyslipidemia4
  • Benign Prostatic Hyperplasia3
  • Acute Myeloid Leukemia2

Frequently asked questions about JW Pharmaceutical

How many clinical trials does JW Pharmaceutical have on ClinicalTrials.gov?
JW Pharmaceutical is listed as the lead sponsor on 77 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
How many of JW Pharmaceutical's trials are in Phase 3?
16 of JW Pharmaceutical's trials are in Phase 3, spread across 14 active drug programs.
What therapeutic areas does JW Pharmaceutical focus on?
JW Pharmaceutical's most-studied conditions on ClinicalTrials.gov are Healthy, Hypercholesterolemia, Type 2 Diabetes Mellitus, Hypertension, Gout.
When are JW Pharmaceutical's next clinical trial readouts?
JW Pharmaceutical has 6 upcoming primary-completion readouts tracked here; the soonest is “To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers”, expected around 2025-11.